Pharma giant Cipla is set to commit $1 billion in importing Moderna vaccines into India but is awaiting clarity from the government.
PTI reports that Cipla is seeking fast track approvals to bring Moderna's single-dose COVID-19 booster vaccine but is seeking waivers from the government of key clauses. As per unnamed sources to PTI Cipla has requested the government for indemnification and exemptions from price capping, bridging trials and basic customs duty. Cipla has shown interest to procure 50 million doses from Moderna for 2022.
Cipla has sought the government's assurance that no price capping would apply for imported vaccines to be provided through private hospitals and that the booster vaccine can be covered under the liberalised pricing policy and kept exempt from any price capping.